Skip to content
stoqly

MeiraGTx Holdings plc

MGTX Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2017–FY2025

Last close Β· Oct 23, 2026

$9.21

5.7%
Revenue Total sales reported in the income statement.
$81.4M
144.6% vs prior year
Operating margin Operating income as a share of revenue.
βˆ’130.2%
363.2 pts
Net income Profit after all expenses, interest and tax.
βˆ’$114M
Free cash flow Cash from operations minus capital spending.
βˆ’$50.2M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
β€”
Market cap Last close times the latest diluted share count, so it is approximate.
$864M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
13.0x
On $0.71 EPS (TTM)

What MeiraGTx Holdings plc does

No business description yet.

Legal name
MeiraGTx Holdings plc
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Mar 30, 2026
Accession Β· CIK
0001104659-26-036494
0001735438

Revenue and margins

MeiraGTx Holdings plc had $81.4M of revenue in fiscal 2025, up 144.6% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was βˆ’$50.2M in fiscal 2025, βˆ’61.7% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

MeiraGTx Holdings plc returned β€” to shareholders in fiscal 2025. The diluted share count rose 15.2%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably MeiraGTx Holdings plc can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $138M$116M$130M$104M$65.9M
Interest coverage βˆ’252.6xβˆ’23.5xβˆ’10.3xβˆ’12.4xβˆ’8.7x
Current ratio 2.7x1.9x2.4x2.0x0.7x
Quick ratio 2.7x1.9x2.4x2.0x0.7x
Total assets $320M$318M$327M$270M$244M
Total liabilities $135M$200M$189M$202M$250M
Shareholders' equity $185M$118M$138M$67.8Mβˆ’$5.8M
Net debt (βˆ’ = net cash) β€”β€”β€”β€”β€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

β€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ“ βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” βœ“ βœ“ βœ“ βœ• βœ• βœ“ βœ• βœ“
Cash from operations exceeds net income βœ“ βœ“ βœ“ βœ• βœ“ βœ“ βœ• βœ“ βœ“
Debt fell relative to assets β€” β€” β€” β€” β€” β€” β€” β€” β€”
Current ratio rose β€” βœ“ βœ“ βœ• βœ• βœ• βœ“ βœ• βœ•
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Gross margin rose β€” β€” β€” β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” β€” β€” βœ“ βœ“ βœ• βœ• βœ“ βœ“
F-score β€” / 3β€” / 6β€” / 62 / 72 / 71 / 72 / 72 / 73 / 7
Accruals ratio βˆ’50.2%βˆ’39.1%βˆ’35.5%1.7%βˆ’20.2%βˆ’17.7%6.6%βˆ’14.5%βˆ’26.4%
Altman Z'' βˆ’21.28βˆ’1.032.702.45βˆ’1.19βˆ’5.17βˆ’5.72βˆ’10.70βˆ’14.65

9 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue β€” β€” $13.3M $15.6M $37.7M $15.9M $14.0M $33.3M $81.4M
Research and development $22.4M $33.6M $24.9M $33.9M $66.7M $85.7M $104M $119M $130M
Operating income βˆ’$31.7M βˆ’$78.1M βˆ’$58.3M βˆ’$62.6M βˆ’$72.8M βˆ’$116M βˆ’$137M βˆ’$164M βˆ’$106M
Interest expense $0.0M $0.0M $0.0M $0.1M $0.3M $4.9M $13.2M $13.3M $12.2M
Pretax income βˆ’$31.0M βˆ’$83.3M βˆ’$54.7M βˆ’$58.0M βˆ’$79.6M βˆ’$130M βˆ’$84.0M βˆ’$148M βˆ’$114M
Income tax $0.0M βˆ’$0.5M $0.0M $0.0M $0.0M β€” $0.0M $0.0M $0.0M
Net income βˆ’$31.0M βˆ’$82.9M βˆ’$54.7M βˆ’$58.0M βˆ’$79.6M βˆ’$130M βˆ’$84.0M βˆ’$148M βˆ’$114M
Net income to common βˆ’$31.9M βˆ’$84.7M βˆ’$54.7M βˆ’$58.0M βˆ’$79.6M βˆ’$130M βˆ’$84.0M βˆ’$148M βˆ’$114M
Diluted EPS βˆ’$3.72 βˆ’$4.47 βˆ’$1.65 βˆ’$1.54 βˆ’$1.80 βˆ’$2.87 βˆ’$1.49 βˆ’$2.12 βˆ’$1.42
Diluted shares 0.01B 0.02B 0.03B 0.04B 0.04B 0.05B 0.06B 0.07B 0.08B
Cash flow
Cash from operations βˆ’$18.1M βˆ’$58.9M $20.0M βˆ’$64.0M βˆ’$10.5M βˆ’$73.1M βˆ’$105M βˆ’$104M βˆ’$46.4M
Capital expenditure $10.5M $11.3M $9.0M $20.9M $46.4M $45.0M $20.2M $5.0M $3.8M
Free cash flow βˆ’$28.6M βˆ’$70.1M $11.1M βˆ’$84.9M βˆ’$56.9M βˆ’$118M βˆ’$126M βˆ’$109M βˆ’$50.2M
Depreciation and amortization $0.7M $2.1M $2.2M $4.2M $7.9M $8.7M $13.7M $12.8M $12.5M
Stock-based compensation $3.0M $17.9M $15.9M $18.4M $20.8M $28.6M $27.7M $25.2M $22.1M
Balance sheet
Cash and short-term investments $8.5M $68.1M $227M $210M $138M $116M $130M $104M $65.9M
Finance lease liabilities β€” β€” $0.1M $0.0M $0.0M β€” β€” β€” $0.1M
Current assets $11.5M $74.7M $269M $273M $183M $154M $160M $124M $91.8M
Current liabilities $21.4M $15.5M $49.2M $54.1M $68.1M $82.1M $67.1M $60.8M $123M
Inventory β€” β€” β€” β€” β€” β€” β€” $0.4M β€”
Property and equipment, net $14.3M $22.0M $23.9M $44.0M $75.9M $109M $116M $103M $105M
Intangible assets β€” β€” $0.0M $2.1M $1.8M $1.3M $1.1M $0.8M $0.6M
Total assets $25.9M $96.9M $324M $364M $320M $318M $327M $270M $244M
Total liabilities $21.9M $15.8M $133M $125M $135M $200M $189M $202M $250M
Shareholders' equity βˆ’$47.4M $81.1M $191M $239M $185M $118M $138M $67.8M βˆ’$5.8M
Margins
Operating margin β€” β€” βˆ’438.4% βˆ’401.9% βˆ’193.0% βˆ’730.9% βˆ’977.8% βˆ’493.4% βˆ’130.2%
EBITDA margin β€” β€” βˆ’421.5% βˆ’375.1% βˆ’172.1% βˆ’676.1% βˆ’879.9% βˆ’454.9% βˆ’114.8%
Net margin β€” β€” βˆ’411.9% βˆ’372.6% βˆ’211.0% βˆ’814.2% βˆ’599.5% βˆ’444.1% βˆ’140.3%
FCF margin β€” β€” 83.2% βˆ’545.5% βˆ’150.9% βˆ’741.6% βˆ’895.6% βˆ’328.9% βˆ’61.7%
Returns
Return on capital employed βˆ’711.6% βˆ’96.0% βˆ’21.2% βˆ’20.2% βˆ’28.9% βˆ’49.3% βˆ’52.8% βˆ’78.6% βˆ’86.9%
Return on equity β€” βˆ’491.9% βˆ’40.3% βˆ’27.0% βˆ’37.5% βˆ’85.5% βˆ’65.7% βˆ’143.5% βˆ’368.2%
Return on assets βˆ’120.1% βˆ’135.0% βˆ’26.0% βˆ’16.9% βˆ’23.3% βˆ’40.6% βˆ’26.1% βˆ’49.6% βˆ’44.4%
Return on tangible equity β€” βˆ’104.5% βˆ’28.7% βˆ’24.5% βˆ’43.3% βˆ’111.4% βˆ’61.3% βˆ’220.6% β€”
Growth
Revenue growth β€” β€” β€” 17.1% 142.2% βˆ’57.8% βˆ’12.0% 137.4% 144.6%
FCF growth β€” β€” β€” βˆ’867.2% β€” β€” β€” β€” β€”
Share count change β€” 121.0% 75.0% 13.8% 17.0% 2.4% 25.0% 23.6% 15.2%
Financial health
Interest coverage βˆ’738.6x βˆ’2,338.4x βˆ’1,198.9x βˆ’450.0x βˆ’252.6x βˆ’23.5x βˆ’10.3x βˆ’12.4x βˆ’8.7x
Current ratio 0.5x 4.8x 5.5x 5.0x 2.7x 1.9x 2.4x 2.0x 0.7x
Quick ratio 0.5x 4.8x 5.5x 5.0x 2.7x 1.9x 2.4x 2.0x 0.7x
Capital allocation
Capex / revenue β€” β€” 67.6% 134.4% 122.9% 282.4% 143.9% 14.9% 4.7%
Stock comp / revenue β€” β€” 119.8% 118.3% 55.1% 179.8% 197.7% 75.7% 27.2%
Quality scores
Piotroski F-score β€” β€” β€” 2.0 2.0 1.0 2.0 2.0 3.0
Altman Z'' βˆ’21.3 βˆ’1.0 2.7 2.4 βˆ’1.2 βˆ’5.2 βˆ’5.7 βˆ’10.7 βˆ’14.7
Accruals ratio βˆ’50.2% βˆ’39.1% βˆ’35.5% 1.7% βˆ’20.2% βˆ’17.7% 6.6% βˆ’14.5% βˆ’26.4%

Source: SEC EDGAR XBRL filings (CIK 0001735438). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open